rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

CorMedix Inc.

CRMD · Nasdaq

Health CarePharmaceuticalsNot moving yet

CRMD stood above a rising 150-day average in 6 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 6.8% below that average now. Pharmaceuticals: 31% of its 74 stocks in an uptrend (−7 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 3
Industry in uptrend
31% -7 in 4 wk
Insider buys, 12 months
$276K
Insider sales, 12 months
$3.0M
Officials’ trades on record
0
Institutions holding
184 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 6 of 52 weeks.

17 Apr – 16 Oct
26%36%46%Apr 26Jun 26Jul 26Sep 26Oct 26

Pharmaceuticals: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$2.1M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months8
Buyers · sellers1 · 4
WhoDidSharesTraded
Janet DillioneDirectorsold10,000at $6.8821 Jan 2026filed 22 Jan 2026
Alan W. DuntonDirectorsold20,000at $13.0030 Dec 2025filed 2 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders184+6 on the quarter
New · exited30 · 23
Reported value$338.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20266,324,111$49.6M+356,536+6.0%
Deep Track Capital, LPunchanged · filed 14 Aug 20266,274,076$49.3M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20263,135,075$24.6M+5,419+0.2%
STATE STREET CORPadded · filed 7 Aug 20262,316,845$18.2M+125,002+5.7%
ROYCE & ASSOCIATES LPadded · filed 14 Aug 20262,176,362$17.1M+288,830+15.3%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,947,014$15.3M+130,107+7.2%
UBS Group AGadded · filed 13 Aug 20261,877,940$14.7M+339,695+22.1%
OBERWEIS ASSET MANAGEMENT INCadded · filed 14 Aug 20261,323,915$10.4M+112,800+9.3%
Alyeska Investment Group, L.P.unchanged · filed 14 Aug 2026850,000$6.7M00.0%
MARSHALL WACE, LLPadded · filed 13 Aug 2026779,535$6.1M+276,570+55.0%
31 Mar 2023 – 30 Jun 2026
59121183Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Janet Dillione Company insiderDirector · last 18 Sep 20267 · 5
Elizabeth Hurlburt Company insiderChief Operating Officer · last 29 Aug 20260 · 4
Kaufman Beth Zelnick Company insiderChief Legal Officer · last 29 Aug 20260 · 1
Susan Blum Company insiderChief Financial Officer · last 29 Aug 20260 · 0
Joseph Todisco Company insiderChief Executive Officer · last 4 Feb 20266 · 2
Alan W. Dunton Company insiderDirector · last 26 Jan 20264 · 2
Gregory Scott Duncan Company insiderDirector · last 26 Jan 20260 · 0
Myron Kaplan Company insiderDirector · last 26 Jan 202618 · 0
Robert A. Stewart Company insiderDirector · last 26 Jan 20261 · 0
Steven W. Lefkowitz Company insiderDirector · last 26 Jan 20267 · 7
Michael David Seckler Company insiderChief Commercial Officer · last 8 Jan 20260 · 0
Erin Mistry Company insiderEVP, Chief Commercial Officer · last 10 Jan 20252 · 0

Same industry

PCRX Pacira BioSciencesLeading+46%
TTRX Turn TherapeuticsLeading+39%
CORT Corcept TherapeuticsLeading+33%
ETON Eton PharmaceuticalsLeading+26%
AMRX Amneal PharmaceuticalsLeading+21%
ABBV AbbVieLeading+20%
TEVA Teva Pharmaceutical IndustriesLeading+20%
VTRS ViatrisLeading+16%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202588.5%
Operating profit marginFY 2025 · to 31 Dec 202548.2%
Free cash flow marginFY 2025 · to 31 Dec 202555.4%
Return on capital employedFY 2025 · to 31 Dec 202523.0%
Cash conversionFY 2025 · to 31 Dec 2025107%
Research spendFY 2025 · to 31 Dec 20256.2%
Share count trendFY 2025 · to 2 Mar 2026-0.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$144.8M
Free cash flowFY 2025 · to 31 Dec 2025$172.8M

Analyst forecasts

No analyst forecasts yet.